Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Perspective
Patient safety is the top priority of every caregiver. Hospitals and health systems never stop searching for ways to improve quality, performance and results…
Blog
The greatest success story of the 20th century is longevity. This is especially true in the United States, where average life expectancy at birth rose by more…
Headline
The AHA the week of July 8 released its Quality Collective Report, which explores quality, safety and performance improvement strategies and insights from…
Headline
In a new “Safety Speaks” conversation, Harry S. Smith, board chair of Valley Health System and member of the AHA Committee on Governance, discusses how Valley…
Headline
“Safety Speaks” is a new Advancing Health series where hospital and health system leaders share successes from their organizations’ patient safety efforts. In…
Blog
The Meharry School of Global Health is the realization of a promise made by Meharry Medical College almost 150 years ago — a promise born out of the legacy of…